GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yili Chuannig Biotechnology Co Ltd (SZSE:301301) » Definitions » Piotroski F-Score

Yili Chuannig Biotechnology Co (SZSE:301301) Piotroski F-Score : N/A (As of May. 25, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Yili Chuannig Biotechnology Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Yili Chuannig Biotechnology Co has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Yili Chuannig Biotechnology Co's Piotroski F-Score or its related term are showing as below:

During the past 6 years, the highest Piotroski F-Score of Yili Chuannig Biotechnology Co was 7. The lowest was 7. And the median was 7.


Yili Chuannig Biotechnology Co Piotroski F-Score Historical Data

The historical data trend for Yili Chuannig Biotechnology Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yili Chuannig Biotechnology Co Piotroski F-Score Chart

Yili Chuannig Biotechnology Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial N/A N/A N/A 7.00 7.00

Yili Chuannig Biotechnology Co Quarterly Data
Dec18 Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A 7.00 7.00 N/A

Competitive Comparison of Yili Chuannig Biotechnology Co's Piotroski F-Score

For the Biotechnology subindustry, Yili Chuannig Biotechnology Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yili Chuannig Biotechnology Co's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Yili Chuannig Biotechnology Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Yili Chuannig Biotechnology Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was 215.422 + 249.281 + 300.414 + 352.615 = ¥1,118 Mil.
Cash Flow from Operations was 1081.397 + 66.448 + 189.705 + 270.569 = ¥1,608 Mil.
Revenue was 1147.466 + 1164.134 + 1242.002 + 1523.218 = ¥5,077 Mil.
Gross Profit was 354.243 + 385.648 + 450.923 + 524.283 = ¥1,715 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(10114.161 + 9761.445 + 10042.128 + 10138.649 + 10573.869) / 5 = ¥10126.0504 Mil.
Total Assets at the begining of this year (Mar23) was ¥10,114 Mil.
Long-Term Debt & Capital Lease Obligation was ¥677 Mil.
Total Current Assets was ¥4,369 Mil.
Total Current Liabilities was ¥2,480 Mil.
Net Income was 136.557 + 95.139 + 79.226 + 175.447 = ¥486 Mil.

Revenue was 986.774 + 955.706 + 881.088 + 1269.733 = ¥4,093 Mil.
Gross Profit was 300.635 + 263.986 + 117.064 + 332.124 = ¥1,014 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(0 + 9457.45 + 9565.284 + 10390.399 + 10114.161) / 5 = ¥9881.8235 Mil.
Total Assets at the begining of last year (Mar22) was ¥0 Mil.
Long-Term Debt & Capital Lease Obligation was ¥1,240 Mil.
Total Current Assets was ¥4,129 Mil.
Total Current Liabilities was ¥2,452 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Yili Chuannig Biotechnology Co's current Net Income (TTM) was 1,118. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Yili Chuannig Biotechnology Co's current Cash Flow from Operations (TTM) was 1,608. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=1117.732/10114.161
=0.11051159

ROA (Last Year)=Net Income/Total Assets (Mar22)
=486.369/0
=

Yili Chuannig Biotechnology Co's return on assets of this year was 0.11051159. Yili Chuannig Biotechnology Co's return on assets of last year was . ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Yili Chuannig Biotechnology Co's current Net Income (TTM) was 1,118. Yili Chuannig Biotechnology Co's current Cash Flow from Operations (TTM) was 1,608. ==> 1,608 > 1,118 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=676.701/10126.0504
=0.06682773

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=1239.83/9881.8235
=0.12546571

Yili Chuannig Biotechnology Co's gearing of this year was 0.06682773. Yili Chuannig Biotechnology Co's gearing of last year was 0.12546571. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=4368.765/2480.186
=1.76146668

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=4128.753/2451.995
=1.68383418

Yili Chuannig Biotechnology Co's current ratio of this year was 1.76146668. Yili Chuannig Biotechnology Co's current ratio of last year was 1.68383418. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Yili Chuannig Biotechnology Co's number of shares in issue this year was 2203.843. Yili Chuannig Biotechnology Co's number of shares in issue last year was 2193.084. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1715.097/5076.82
=0.337829

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1013.809/4093.301
=0.24767516

Yili Chuannig Biotechnology Co's gross margin of this year was 0.337829. Yili Chuannig Biotechnology Co's gross margin of last year was 0.24767516. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=5076.82/10114.161
=0.50195167

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=4093.301/0
=

Yili Chuannig Biotechnology Co's asset turnover of this year was 0.50195167. Yili Chuannig Biotechnology Co's asset turnover of last year was . ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+0+1+1
=8

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Yili Chuannig Biotechnology Co has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

Yili Chuannig Biotechnology Co  (SZSE:301301) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Yili Chuannig Biotechnology Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Yili Chuannig Biotechnology Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Yili Chuannig Biotechnology Co (SZSE:301301) Business Description

Traded in Other Exchanges
N/A
Address
No. 516, Almatua Village, Yining Park, Horgos Economic Development Zone, Xinjiang, Ili, CHN, 835000
Yili Chuannig Biotechnology Co Ltd adopts the most advanced and mature international biological fermentation, chemical extraction, enzymatic hydrolysis, control and energy saving, and environmental protection technology. The main products of the company include erythromycin thiocyanate, cephalosporin intermediates, penicillin intermediates, and crude ursodeoxycholic acid.

Yili Chuannig Biotechnology Co (SZSE:301301) Headlines

No Headlines